Search

569 Result(s)
Sort by

Boehringer Ingelheim Social Engagements

Boehringer Ingelheim Social Engagements

Boehringer Ingelheim Social Engagements Contributes to company commitment to impact 50 million people in vulnerable communities by 2030 through supporting social entrepreneurs and innovative solutions
Questions and Answers

Questions and Answers

Answers to common questions from both patients and health care professionals regarding Compassionate Use of experimental medications.
Women in STEM 2022

Women in STEM 2022

Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM.
Veronika Kohlbrenner

Veronika Kohlbrenner

Veronika Kohlbrenner, Patient Safety Physician in Therapeutic Area Inflammation, tells us how she is able to work across different levels of the drug development process.
Vaccine bluetongue virus serotype 3 sheep cattle

Vaccine bluetongue virus serotype 3 sheep cattle

BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.
Valerie Nock

Valerie Nock

My career challengeFunctional Areas at Boehringer Ingelheim
FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
EHS management approach

EHS management approach

We protect our employees, facilities and the environment from harmful influences, conserve natural resources and promote environmental awareness